Ethics and regulatory oversight in implantable BCI human subjects research

• Implantable BCI human subjects research requires bridging ethical considerations and regulatory oversight to align with advancing commercial devices.¹
• A Frontiers perspective frames the gap between ethics and regulation as decision-relevant for patient advocacy and policy as commercial BCIs advance.^{1 1}

Weekly enrichment (2026-07-20)

• The underlying perspective is Wilkins, Coffin, Pham, Klein and Marathe, “Mind the gap: bridging ethical considerations and regulatory oversight in implantable BCI human subjects research,” published in Frontiers in Human Neuroscience (2025;19:1633627; received 22 May 2025, accepted 7 July 2025), with corresponding author Tara Coffin of WCG Clinical.^{2 3}
• The paper centers on the role of U.S. Institutional Review Boards (IRBs), which are federally mandated to protect participant rights and welfare; it argues IRBs lack repeated exposure to iBCI studies because the number of such trials remains low relative to other therapeutic areas, forcing boards to “relearn” the technology with each new protocol.^{2 3}
• iBCIs are almost always investigational and, given surgical risk, cyberattack risk, and possible long-term personality or neuronal changes, will likely always be regulated as FDA Class III (highest-risk) devices requiring the Investigational Device Exemption (IDE, 21 CFR 812) and Premarket Approval (PMA) pathways.^{2 3}
• FDA published formal iBCI device guidance in 2021 aimed at patients with paralysis or amputation, emphasizing device design disclosure, non-clinical bench and animal testing, human factors engineering, and cybersecurity/risk management before clinical performance testing.^{2 3}
• The authors flag that current regulatory mechanisms concentrate on premarket safety and efficacy with little emphasis on long-term surveillance or post-market follow-up, a gap that is problematic for devices that induce neural changes unfolding over years.^{2 3}
• Informed consent is singled out as uniquely difficult: candidates may hold therapeutic misconceptions in proof-of-concept studies, may experience improvements (faster communication, better prosthetic control) that are not sustainable after the trial, and voluntariness can be compromised if participants feel pressure to reduce caregiver burden.^{2 3}
• The perspective catalogs iBCI-specific risks including device migration and malfunction, unintended stimulation, altered sense of agency/authenticity, neural-data privacy and unauthorized access, stigma, device dependence, and unresolved post-trial responsibility for maintenance if a manufacturer folds or pivots.^{2 3}
• A companion review of neural-device research similarly concludes that no definitive ethical or regulatory frameworks—or even standard practices—yet exist for post-trial responsibilities, reinforcing the article’s call for specialized IRB training, iterative consent, and external cybersecurity expertise.⁴

Footnotes

1. https://news.google.com/rss/articles/CBMinAFBVV95cUxPemRfQm5kQlFtYW1BUzB5X3U4YnE2a0dVdWFCZGdiTFBOVG1WVjFZcVVQQmJ6bHlldFBoYVBCdzJndzFVQ2Jrd09GbDJIbmU3RV9LUmp2MlhfN2pFN2FROGdmQ3g3dGVwZVFsX0Vla3pEajlXZklDMGRnLVZqTzJFbXNPaVNJV2hzU2dqWThfVU5wa0tfLWJsZlJvR2U?oc=5 ↩ ↩² ↩³

2. https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2025.1633627/full ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

3. https://pmc.ncbi.nlm.nih.gov/articles/PMC12325254/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

4. https://escholarship.org/content/qt31p177c5/qt31p177c5_noSplash_935bc42ab6a9a8b24c6420a3cecaf520.pdf ↩